When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

by Ishai Menache, Jeevan Pathuri, David Simchi-Levi and Tom Linton Companies face a variety of complex challenges in designing and optimizing their supply chains. Increasing their resilience ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Attorney General Kwame Raoul is warning Illinois residents seeking GLP-1 medications – Ozempic, Wegovy, Mounjaro, Zepbound ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Lory Osborn says the Wegovy she was prescribed 15 months ago did more than help her lose 75 pounds — over a quarter of her ...